FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.144,64 -652,12 (-1,09%)
Inventiva S.A. (0RNK.L)
| Chiusura precedente | 3,5588 |
| Aperto | 2,9874 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 2,9874 - 2,9874 |
| Intervallo di 52 settimane | 1,9200 - 4,7450 |
| Volume | |
| Media Volume | 1.962 |
| Capitalizzazione | 567.946 |
| Beta (5 anni mensile) | 0,96 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,2670 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireInventiva reports its 2023 first-half financial results and provides a corporate update
Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million1, and long-term deposit at €9.3 million2, as of June 30, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectivelRevenues amounted to €1.9 million for the first half of 2023In August 2023, Inventiva received a financing of approximately €35.7 million from new and existing investors consisting of €30.6 million from a capital increase and €5.1 million issuance of royalty cert
- GlobeNewswire
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
Hepalys Pharma, Inc. is a new company created by Catalys Pacific and in which Inventiva has a 30% ownership position. Under the exclusive licensing agreement, Inventiva will receive a $10 million upfront payment, and is eligible to receive up to $ 231 million in clinical, regulatory and commercial milestone payments in addition to tiered royalties from mid double digits to low twenties based on net sales of lanifibranor in Japan and South Korea.Pending regulatory approvals, Hepalys Pharma, Inc.
- GlobeNewswire
Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates
Daix (France), Long Island City (New York, United States), August 31, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today announced an approximately €35.7 million financing. The financing consists of two transactions: (i) a capital increase rese
